Quantum Genomics Corp. (QGC), a global biotech company developing
new drugs for metabolic and cardiovascular diseases, announced
partnership agreements with Inserm, the French national institute for
health and medical research and the CNRS, France´s national center for
scientific research, and University Paris Descartes. The agreement
brings together some of the best scientific skills in the field of
cardiovascular diseases from two leading life science research
organizations and a premier university along with biotechnology
business experience from QGC, to successfully co-develop innovative
The agreement covers a lead molecule derived from discoveries by
teams led respectively by Dr Catherine Llorens-Cortes, director of
Inserm Unit 691, based in the College de France and by Prof. Bernard
P. Roques at Inserm Unit 640, itself based in the University of Paris
The purpose of the agreement is to co-develop innovative drugs for
hypertension and related cardiovascular diseases. Under the terms of
the contract, QGC acquires rights to exploit three patents and
associated know-how. Inserm and CNRS will work on the physiopathology,
chemistry and the understanding of the compound´s mechanism of action
whereas QGC will handle preclinical and clinical development and
The first lead molecule to be developed will be QGC001, a new
chemical entity. This compound acts according to a new biological
mechanism with a huge potential to facilitate control of blood
pressure in patients who are resistant to currently available
anti-hypertension drugs. QGC expects to start the first clinical trial
in humans in 2008.
"We are delighted to be partnering with Inserm and CNRS, two of
the world´s leading healthcare research organizations," said Lionel
Segard, Chairman and CEO of QGC. "This project lets QGC demonstrate
its ability to develop new drugs in compliance with international
regulatory guidelines. It also significantly reinforces QGC´s
potential in R&D in the field of cardiovascular diseases."
"This partnership with QGC gives us an excellent opportunity to
accelerate the pre-clinical and clinical development of a project
based on work carried out in our labs in close cooperation with
Bernard Roques´ team," said Catherine Llorens Cortes, director of
Inserm Unit 691.
Cardiovascular diseases are one of the main causes of death in
humans. Hypertension in particular is one of the major determining
factors in premature death. The risk of myocardial infarction, stroke,
kidney failure, heart failure or other complications doubles with
every 20/10mmHg rise in blood pressure. At least 30% of people have
hypertension. Hundreds of millions of people worldwide suffer from
hypertension complications despite medical advice on food and health
habits and the existence of several treatments. The market for
hypertensive drugs is expected to double between 2005 and 2010.
About Quantum Genomics Corp.
QGC is a biotechnology company seeking to develop new therapies in
areas where an unmet medical need exists. QGC focus is on
metabolism-related diseases and cardiovascular pathologies. It will
co-develop some products with academic teams and will set up strategic
alliances and commercial partnerships to cover all areas of research
in life sciences.
The company is headquartered in Jersey City, New Jersey, USA. It
has a European office in France under the leadership of Lionel Segard.
For more information go to www.Quantum-Genomics.com